01 Growing Adoption of Connected and Personalized PAP Devices The positive airway pressure devices market is increasingly shifting toward connected devices that combine therapy delivery with digital monitoring and personalized treatment support. Manufacturers are integrating AI, machine learning, cloud connectivity, and mobile applications to improve therapy comfort, adherence, and monitoring. These technologies allow clinicians and patients to access therapy information remotely and support more individualized sleep apnea management. In early 2026, ResMed introduced Smart Comfort, an FDA-cleared AI-enabled feature designed to recommend personalized comfort settings to help patients start and remain on CPAP therapy.
02 Expansion of Home-Based Sleep Therapy Another important positive airway pressure devices market trend is the growing shift toward home-based diagnosis and treatment. Smaller, quieter, connected, and easier-to-use PAP devices are supporting treatment outside traditional clinical settings. Home-based care can improve convenience and access while enabling remote monitoring of therapy adherence and outcomes, particularly as healthcare systems increasingly emphasize decentralized respiratory and sleep care. In July 2026, Resvent received FDA 510(k) clearance for its RXiBreeze 20C PAP system for treating obstructive sleep apnea in adults in home, hospital, and institutional environments.
01 Rising Prevalence and Diagnosis of Sleep Apnea The increasing diagnosis of obstructive sleep apnea is driving demand for positive airway pressure devices, particularly CPAP systems. PAP therapy remains a standard treatment option for obstructive sleep apnea, while greater awareness and access to sleep testing are encouraging more patients to seek treatment. The availability of home sleep testing and different PAP modalities is also improving access to therapy.
01 Challenges With Long-Term Patient Adherence Patient adherence remains an important restraint for the positive airway pressure devices market because some users experience discomfort, mask-related problems, pressure intolerance, or difficulty adjusting to therapy. Inconsistent use can reduce treatment effectiveness and may discourage long-term device utilization. Manufacturers therefore need to improve comfort, usability, and individualized therapy settings to support sustained use.
01 Expansion of Remote Monitoring and Home-Based PAP Therapy The growing use of home-based PAP initiation and remote monitoring is creating opportunities for device manufacturers to develop connected systems that support treatment outside traditional sleep laboratories. Cloud-based data can help clinicians monitor therapy usage and effectiveness, while telemedicine and digital applications can provide timely follow-up and patient support. These capabilities can improve convenience and expand access to sleep-disorder treatment.
01 Balancing Advanced Features With Affordability and Usability Manufacturers face the challenge of incorporating connectivity, automated pressure adjustment, digital monitoring, and other advanced features while keeping devices comfortable, reliable, and affordable. More sophisticated systems can increase development and manufacturing complexity, while patients still require simple interfaces, effective masks, and convenient therapy. Regulatory requirements for connected and AI-enabled medical devices also add complexity to product development.
May 2026 ResMed launched the AirSense 12 platform featuring enhanced digital health capabilities, AI-powered therapy support, and improved patient connectivity for obstructive sleep apnea treatment.
February 2026 Fisher & Paykel Healthcare expanded its home respiratory care portfolio with new PAP mask technologies designed to improve patient comfort, fit, and long-term therapy adherence.
October 2025 ResMed introduced new AirFit™ mask solutions with upgraded cushion technology to improve comfort, reduce air leakage, and enhance positive airway pressure therapy outcomes.
June 2025 React Health expanded its sleep therapy portfolio by launching new CPAP and BiPAP devices with cloud-based patient monitoring and remote therapy management capabilities.